Program
stapokibart
Also written as “CM310”, “Stapokibart” and “Stapokibart injection”.
Its studies are mostly in Dermatitis, Atopic · Rhinitis, Allergic, Seasonal · Rhinitis, Allergic · Nasal Polyps · Asthma, led by 3 companies.
Drug pageStapokibart: every studyAll 36 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Keymed Biosciences | 246 open or running | phase 3since Feb 17, 2022 | Mar 12, 2021 | Feb 2027phase 3 · NCT07106372 |
| Chengdu Kangnuoxing Biopharma,Inc.its history only | 33 open or running | phase 3since Sep 30, 2025 | Sep 30, 2025 | Dec 2026phase 3 · NCT07678931 |
| CSPC Pharmaceutical Groupits history only | 22 open or running | phase 3since Feb 27, 2023 | Feb 27, 2023 | Apr 29, 2032phase 3 · NCT06547333 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Keymed Biosciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 10 studies since Mar 12, 2021.
- Jan 19, 2023Named stapokibartINNProposed as its International Nonproprietary Name in WHO's List 128 · before, CM310
- Jan 27, 2023Phase 2 study in Dermatitis, AtopicNCT05715320 · 160 enrolled · China
- Jun 2, 2023Phase 3 study in Rhinitis, AllergicNCT05908032 · 108 enrolled · China
- Jun 8, 2023Phase 2 study in Rhinitis, AllergicNCT05908721 · 100 enrolled · China
- Oct 30, 2023Phase 2 study in Dermatitis, AtopicNCT06116565 · 263 enrolled · China
- Nov 29, 2023Phase 2 study in Dermatitis, AtopicNCT06162507 · 24 enrolled · China
- Nov 29, 2023Phase 1 study in HealthyNCT06161090 · 33 enrolled · China
- Dec 4, 2023Phase 2 study in Rhinitis, Allergic, SeasonalNCT06171074 · 100 planned · China
- Dec 5, 2023Phase 1 study in HealthyNCT06171048 · 236 planned · China
- Feb 18, 2024Phase 3 study in Dermatitis, AtopicNCT06277765 · 180 enrolled · China
- May 16, 2024Phase 3 study in Prurigo NodularisNCT06424470 · 200 enrolled · China
- Jul 2, 2024Phase 3 study in Dermatitis, AtopicNCT06495229 · 180 enrolled · China
- Jul 24, 2024Phase 2 study in Rhinitis, AllergicNCT06525597 · 120 planned · China
- Apr 30, 2025Phase 3 study in Dermatitis, AtopicNCT06956196 · 240 planned · China
- Aug 5, 2025Phase 3 study in Dermatitis, AtopicNCT07106372 · 240 planned · China
Ahead
- Feb 2027Primary completion: phase 3 study in Dermatitis, AtopicNCT07106372
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 24 Keymed Biosciences leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07106372Dermatitis, Atopic · China | 3 | Not yet recruiting | Feb 2027 | 240 |
| NCT06956196Dermatitis, Atopic · China | 3 | Not yet recruiting | May 2026 | 240 |
| NCT06525597Rhinitis, Allergic · China | 2 | Recruiting | Oct 30, 2025 | 120 |
| NCT06495229Dermatitis, Atopic · China | 3 | Active, not recruiting | Aug 30, 2026 | 180 |
| NCT06424470Prurigo Nodularis · China | 3 | Completed | Feb 11, 2026 | 200 |
| NCT06277765Dermatitis, Atopic · China | 3 | Completed | Jan 23, 2025 | 180 |
| NCT06171048Healthy · China | 1 | Not yet recruiting | Apr 30, 2025 | 236 |
| NCT06171074Rhinitis, Allergic, Seasonal · China | 2 | Not yet recruiting | Mar 30, 2025 | 100 |
| NCT06162507Dermatitis, Atopic · China | 2 | Completed | Jul 4, 2024 | 24 |
| NCT06161090Healthy · China | 1 | Completed | Jan 13, 2020 | 33 |
| NCT06116565Dermatitis, Atopic · China | 2 | Completed | Nov 26, 2025 | 263 |
| NCT05908721Rhinitis, Allergic · China | 2 | Completed | Dec 10, 2023 | 100 |
| NCT05908032Rhinitis, Allergic · China | 3 | Completed | Dec 4, 2023 | 108 |
| NCT05715320Dermatitis, Atopic · China | 2 | Completed | Jul 18, 2024 | 160 |
| NCT05702450Healthy · China | 1 | Completed | Jul 26, 2023 | 240 |
| NCT05579925Dermatitis, Atopic · China | 2 | Completed | Jul 28, 2023 | 24 |
| NCT05452343Chronic Pruritus of Unknown Origin | 2 | UNKNOWN | Mar 1, 2024 | 50 |
| NCT05265923Dermatitis, Atopic · China | 3 | Completed | Oct 31, 2023 | 500 |
| NCT05186909Asthma · China | 2 | Completed | Sep 13, 2023 | 52 |
| NCT05131464Chronic Rhinosinusitis With Nasal Polyps · China | 2 | Completed | Jan 31, 2024 | 46 |
| NCT04893707Dermatitis, Atopic · China | 2 | Completed | Feb 3, 2023 | 127 |
| NCT04893941Moderate-to-severe Atopic Dermatitis · China | 2 | Completed | Jan 22, 2021 | 39 |
| NCT04805411Dermatitis, Atopic · China | 2 | Completed | Nov 8, 2021 | 120 |
| NCT04805398Disease · China | 2 | Completed | Mar 18, 2022 | 56 |
How it is read
Names in the registry
- “CM310”, 22 entries
- “Stapokibart”, 2 entries
- “Stapokibart injection”, 2 entries
- “Stapokibatrt”, 2 entries
- “Stapokibart Injection”, 1 entry
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 12 studies
- Rhinitis, Allergic, Seasonal, 3 studies
- Rhinitis, Allergic, 3 studies
- Nasal Polyps, 2 studies
- Asthma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.